| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.006 | 0.8 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | necrostatin-7 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.8 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.8 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.8 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |